Relative replication fitness of efavirenz-resistant mutants of HIV-1: Correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V
- 21 June 2006
- Vol. 353 (1) , 184-192
- https://doi.org/10.1016/j.virol.2006.05.021
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Modeling and Estimation of Replication Fitness of Human Immunodeficiency Virus Type 1 In Vitro Experiments by Using a Growth Competition AssayJournal of Virology, 2006
- Treatment for Adult HIV InfectionJAMA, 2004
- Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)Journal of Virology, 2004
- The Y181C Substitution in 3′-Azido-3′-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated PrimerJournal of Biological Chemistry, 2003
- Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus ReplicationJournal of Virology, 2003
- Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor TherapyJournal of Virology, 2001
- Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 1994
- Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse TranscriptaseJournal of General Virology, 1994
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993
- 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 1992